Published in J Infect Dis on July 01, 2008
Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX (imPACT) | NCT01629316
The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis (2011) 16.88
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Rethinking prevention of HIV type 1 infection. Clin Infect Dis (2010) 4.19
HIV-1 treatment as prevention: the good, the bad, and the challenges. Curr Opin HIV AIDS (2011) 3.39
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Universal testing and treatment as an HIV prevention strategy: research questions and methods. Curr HIV Res (2011) 2.60
HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. Clin Infect Dis (2013) 1.77
Engaging men in prevention and care for HIV/AIDS in Africa. PLoS Med (2012) 1.71
Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada. PLoS One (2010) 1.65
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One (2011) 1.53
A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS One (2012) 1.50
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
Correlates of retention in HIV care after release from jail: results from a multi-site study. AIDS Behav (2013) 1.39
Combining qualitative and quantitative evidence to determine factors leading to late presentation for antiretroviral therapy in Malawi. PLoS One (2011) 1.38
Shifting the paradigm: using HIV surveillance data as a foundation for improving HIV care and preventing HIV infection. Milbank Q (2013) 1.33
Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep (2010) 1.26
Early identification of HIV: empirical support for jail-based screening. PLoS One (2012) 1.15
Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One (2012) 1.08
AIDS vaccines and preexposure prophylaxis: is synergy possible? AIDS Res Hum Retroviruses (2010) 1.07
HIV treatment as prevention: the key to an AIDS-free generation. J Food Drug Anal (2013) 1.05
Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS (2010) 1.01
HIV prevention: What have we learned from community experiences in concentrated epidemics? J Int AIDS Soc (2008) 1.01
Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti. J Acquir Immune Defic Syndr (2013) 1.01
Use of HIV case surveillance system to design and evaluate site-randomized interventions in an HIV prevention study: HPTN 065. Open AIDS J (2012) 1.00
HIV mortality in urban slums of Nairobi, Kenya 2003-2010: a period effect analysis. BMC Public Health (2013) 0.98
Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. PLoS Med (2011) 0.97
Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Res Treat (2012) 0.96
XVII International AIDS Conference: From Evidence to Action - Clinical and biomedical prevention science. J Int AIDS Soc (2009) 0.93
Modeling the impact on HIV incidence of combination prevention strategies among men who have sex with men in Beijing, China. PLoS One (2014) 0.93
Next steps for Ukraine abolition of HIV registries, implementation of routine human immunodeficiency virus testing and expansion of services. Addiction (2010) 0.93
InterVA versus Spectrum: how comparable are they in estimating AIDS mortality patterns in Nairobi's informal settlements? Glob Health Action (2013) 0.91
Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020. AIDS Res Ther (2011) 0.91
Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc (2008) 0.90
Leveraging HIV treatment to end AIDS, stop new HIV infections, and avoid the cost of inaction. Clin Infect Dis (2014) 0.89
A qualitative study of patient motivation to adhere to combination antiretroviral therapy in South Africa. AIDS Patient Care STDS (2015) 0.88
HIV prevention services and testing utilization behaviors among men who have sex with men at elevated risk for HIV in Chongqing, China. Biomed Res Int (2014) 0.87
Operationalizing treatment as prevention in Los Angeles County: antiretroviral therapy use and factors associated with unsuppressed viral load in the Ryan White system of care. AIDS Patient Care STDS (2012) 0.87
Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS (2015) 0.87
Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis. PLoS One (2011) 0.86
Evaluating the Impact of Test-and-Treat on the HIV Epidemic among MSM in China Using a Mathematical Model. PLoS One (2015) 0.85
HIV epidemic control-a model for optimal allocation of prevention and treatment resources. Health Care Manag Sci (2013) 0.84
Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis. Curr HIV Res (2011) 0.84
Cohort Profile: HAART Observational Medical Evaluation and Research (HOMER) cohort. Int J Epidemiol (2014) 0.84
A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Med (2017) 0.83
Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in British Columbia. AIDS Behav (2014) 0.83
Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level. PLoS One (2013) 0.83
Are Low- and Middle-Income Countries Repeating Mistakes Made by High-Income Countries in the Control of HIV for Men who have Sex with Men? J AIDS Clin Res (2012) 0.83
Assessing the population health impact of market interventions to improve access to antiretroviral treatment. Health Policy Plan (2011) 0.82
Estimated HIV Incidence in California, 2006-2009. PLoS One (2013) 0.82
Expanded Highly Active Antiretroviral Therapy Coverage - A Powerful Strategy to Curb Progression to AIDS, Death and New Infections. Eur Infect Dis (2009) 0.81
The use of highly active retroviral therapy to reduce HIV incidence at the population level. CMAJ (2008) 0.80
How HIV treatment could result in effective prevention. Future Virol (2010) 0.80
Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study. BMC Res Notes (2014) 0.80
Human Resources for Treating HIV/AIDS: Are the Preventive Effects of Antiretroviral Treatment a Game Changer? PLoS One (2016) 0.79
Optimizing an HIV testing program using a system dynamics model of the continuum of care. Health Care Manag Sci (2015) 0.78
Treatment as prevention--where next? Curr HIV/AIDS Rep (2014) 0.78
Antiretroviral therapy use among HIV-infected men who have sex with men attending a sexually transmitted diseases clinic. J Acquir Immune Defic Syndr (2010) 0.78
Late-stage disease at presentation to an HIV clinic in eastern Tanzania: A retrospective cross-sectional study. Malawi Med J (2015) 0.77
Estimating the Impact of Earlier ART Initiation and Increased Testing Coverage on HIV Transmission among Men Who Have Sex with Men in Mexico using a Mathematical Model. PLoS One (2015) 0.77
Modeling scenarios for the end of AIDS. Clin Infect Dis (2014) 0.76
Impact of Antiretroviral Therapy on the Spread of Human Immunodeficiency Virus in Chaoyang District, Beijing, China: Using the Asian Epidemic Model. Chin Med J (Engl) (2017) 0.75
HIV treatment as prevention: contradictory perspectives from dynamic mathematical models. ScientificWorldJournal (2014) 0.75
Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. PLoS One (2015) 0.75
Expanded antiretroviral treatment, sexual networks, and condom use: Treatment as prevention unlikely to succeed without partner reduction among men who have sex with men in China. PLoS One (2017) 0.75
Prevalence and risk factors of HIV and syphilis, and knowledge and risk behaviors related to HIV/AIDS among men who have sex with men in Chongqing, China. J Biomed Res (2015) 0.75
Need for improved access to HIV prevention programmes. Indian J Med Res (2010) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS (2002) 5.21
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 5.00
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. BMJ (2011) 4.54
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med (2003) 4.46
Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ (2003) 4.38
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr (2009) 3.67
Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction (2006) 3.65
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J (2006) 3.49
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr (2006) 3.38
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ (2003) 3.19
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet (2011) 3.14
Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis (2010) 3.12
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility. Int J Drug Policy (2008) 3.05
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (2007) 3.04
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology (2002) 2.99
Food insecurity is associated with incomplete HIV RNA suppression among homeless and marginally housed HIV-infected individuals in San Francisco. J Gen Intern Med (2008) 2.97
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog (2007) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA (2008) 2.77
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS (2002) 2.74
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr (2005) 2.74
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Displacement of Canada's largest public illicit drug market in response to a police crackdown. CMAJ (2004) 2.63
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ (2004) 2.62
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis (2011) 2.60
Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS (2009) 2.55
Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther (2007) 2.49
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis (2005) 2.48
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis (2005) 2.42
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med (2007) 2.41
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS (2007) 2.39
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend (2006) 2.33
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 2.32
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
The association between food insecurity and mortality among HIV-infected individuals on HAART. J Acquir Immune Defic Syndr (2009) 2.31
A review of barriers and facilitators of HIV treatment among injection drug users. AIDS (2008) 2.21
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ (2003) 2.18
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One (2009) 2.16
Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS (2008) 2.14
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther (2004) 2.14